Cyclotek is thrilled to unveil significant expansions at two strategic locations in Melbourne, marking a significant leap forward in our mission to revolutionize cancer treatment and diagnosis through advanced radiopharmaceuticals and radioactive medical devices. These expansions underscore our commitment to pioneering personalized diagnostics and therapies that enhance patient outcomes.
Building on the funding provided by the Australian Government, Cyclotek’s new Victorian facilities expand upon our existing radiolabelling and quality control capabilities and our relationship with innovative infrastructure provider, Comecer, for our specialised shielded hot cell isolators and dispensing capabilities.
Supported by the Australian Government, Cyclotek has significantly enhanced its production capabilities and research facilities. Partnering with Comecer, a leader in nuclear medicine technology, the facilities will include advanced shielded hot cell isolators and dispensing systems. This collaboration not only signifies our radiolabelling and quality control operations but also solidifies our position as an industry pacesetter.
The new expansions will drastically increase our capacity to work with cutting-edge medical radioisotopes, including 64/67Cu, 177Lu, 212Pb, and 225Ac, across alpha, beta, gamma, and auger emission paradigms. This advancement is crucial for supporting a growing network of theranostic clinical trials across Australia, New Zealand, and the ASEAN region.
Dr. Mark Frazzetto, Director of Quality and Research, highlighted Cyclotek’s comprehensive approach, “We are uniquely equipped to support the pharmaceutical and biotech sectors with our full-spectrum CDMO services. From pioneering R&D to large-scale manufacturing, our structures allow us to adhere to phase appropriate regulatory standards.”
Further enhancing our research capabilities, Cyclotek has also formed a strategic alliance with the University of Melbourne to establish a top-tier radiopharmaceutical research and development centre at the University’s Parkville campus. This facility will be pivotal in advancing cancer targeting technologies and developing novel radiopharmaceuticals for both cancer and neurological diseases.
Joshua Seale, Director of Facilities and Operations, emphasized the strategic importance of the new sites, “These facilities (Parkville and Melbourne Northern) will propel Cyclotek to the forefront of global radiopharmaceutical development, ensuring we remain at the cutting edge of theranostic applications and clinical trial support.”
These expansions reflect Cyclotek’s dedication to leading the renaissance in radiopharmaceutical development, ensuring that advanced diagnostic and therapeutic options are accessible to patients in our regions and beyond. With ongoing investments in research, infrastructure, and strategic partnerships, Cyclotek is poised to drive substantial clinical advancements in the field.
For further information, please contact: Mr Greg Santamaria – enquiries@cyclotek.com
Cyclotek is the leading radiopharmaceutical manufacturer in Australia and New Zealand. We manufacture diagnostic and therapeutic radiopharmaceuticals for supply into clinical trials and for clinical use.
At Cyclotek, we are committed to improving patient outcomes by making diagnostic and therapeutic radiopharmaceuticals accessible. PET tracers provide patient specific insights into their disease state, leading to earlier diagnosis, more accurate assessment of disease extent, and improved treatment planning and monitoring. Paired with radionuclide therapies, these products offer a comprehensive, non-invasive disease management option.
Our dedication to innovation drives our continuous development of new radiopharmaceuticals.
This helps provide our customers a growing range of tools that enhance the understanding of each patient’s health, contributing to more cost-effective healthcare solutions.
At Cyclotek, we are not just a manufacturer, we are a hub of innovation. Our commitment to quality, safety, supply and customer service ensures that healthcare providers have the best tools available for precise diagnostics and therapies, fostering improved patient care.
Through our unwavering focus on excellence, we aim to make a lasting, positive impact on healthcare.
[contact-form-7 id=”714″ title=”Update Form”]
